2nd Jul 2007 07:01
Plant Impact PLC02 July 2007 Press Release 2 July 2007 Plant Impact plc ("Plant Impact" or "the Group") Audited Final Results for the year ended 31 March 2007 Plant Impact plc (AIM:PIM), a global developer of plant stress managementtechnologies, today announces its audited final Results for the year ended 31March 2007. Corporate Highlights• Successful listing on AIM in October 2006, raising £3.3m (net of expenses). • Sales o Continued development of sales in the Middle East o First sales in the USA and EU of nutrient products o First sales in the European Home and Garden market including a Tesco own label product • Distribution agreements with Certis Europe BV and Doff Portland • Strengthened management team Research & Development Highlights• BugOil(R) registration in America and United Kingdom in progress • Positive field trial results, 40 trials undertaken in Europe, East Africa and the Middle East • Research agreement with Lancaster University Financial Highlights• Sales increase of 9% • Loss on ordinary activities before taxation for the year ended 31 March 2007 of £1.9m (15 months ending 31 March 2006: loss £1.1m) • Cash and liquid resources at 31 March 2007 of £3.1m (2006: £0.5m) Martin Robinson, Chairman of Plant Impact plc, commented: "The Group has made significant progress over the year. The flotation of PlantImpact on AIM in October 2006 has given the Group the financial stability totake the business to the next significant stage of its development." "Plant Impact has continued to make progress in the Middle East, North Africaand European markets through its established distribution channels. Sales inthe USA and in the European home and garden sector in the latter part of theyear have opened up these markets for the Group sooner than we had expected.Evaluation field trials, on both the Group's crop nutrient and botanicalpesticide products, are being conducted by a number of multi-nationalagricultural chemicals companies in America, Japan, the Middle East and NorthAfrica, Spain and Chile, with a view to them entering into distribution and/orlicensing agreements. We remain confident of the successful development andcommercialisation of our products." For further information, please contact:Plant Impact plcPeter Blezard, Chief Executive Tel: + 44 (0) 1772 333 [email protected] www.plantimpact.com Grant Thornton Corporate FinanceNominated Adviser Philip Secrett Tel: +44 (0) 870 991 [email protected] www.gtuk.com Media enquiries:AbchurchJustin Heath/ Ashley Tapp Tel: +44 (0) 20 7398 [email protected] www.abchurch-group.com Chairman's Statement I am very pleased to present Plant Impact's results for the year ended 31 March2007 during which the Group has made significant progress. The flotation of theGroup on AIM in October 2006 has given the Group the financial stability to takethe business to the next significant stage of its development, enabling it toexpand its sales team, invest in the registration of BugOil(R) (the Group's pestcontrol product), fund further trials to demonstrate the efficacy of theproducts and to negotiate distribution and licensing deals around the world,where the improved balance sheet should put the Group in a stronger negotiatingposition. Financial Review During the year ended 31 March 2007, Plant Impact has traded in line withexpectations. Turnover for the year was £377,237, compared with £345,811 for thefifteen months ended 31 March 2006. The Group operating loss was £1,495,979compared with £920,094 for the fifteen months ended 31 March 2006, the increasereflecting the additional expenditure on people, product development and fieldtrials during the year. Interest charges, accounting for share-based payments(£107,641) and the redemption premium (£394,079) on the convertible loan stockincreased the loss before taxation to £1,869,237 compared with £1,060,388 forthe fifteen months ended 31 March 2006. All outstanding loans were converted into equity on flotation, discharging theGroup's liability in respect of convertible loan stock, including the redemptionpremium thereon, a preferred loan and two short-term loans, in total amountingto £1,647,000. A further £3.3 million, net of expenses, was raised by a placingon to the AIM market, resulting in a much stronger balance sheet. Net assets at31 March 2007 were £3,481,379 including cash and short term investments of£3,077,959, compared with net liabilities of £180,801 with cash of £446,770 at31 March 2006. Commercial development All of Plant Impact's sales to date have been generated from the Group's rangeof nutrient products. The majority of the Group's sales in the year were in the Middle East and NorthAfrica ("MENA"). The Group has a number of established distribution agreementsin this region and is represented by Pi-MENA, an independent sales agency basedin Jordan, working exclusively for Plant Impact. The Directors have decided toconcentrate their efforts in the Middle East on the distribution relationshipsin Saudi Arabia, Egypt, Syria, Morocco and Algeria, being the markets that showthe best prospects for growth in the MENA region. In December 2005, Plant Impact entered into a distribution agreement with CertisEurope BV, for its crop nutrient range, covering Spain and Portugal. The firstsales were recorded in February 2006 and have continued to grow since then. Inaddition, the Group provides marketing support to Certis in the form of sharingthe costs of a dedicated salesman and direct marketing costs, such as productliterature, and the cost of arranging sales seminars and training for growers. In December 2006, the Group entered into a distribution agreement with DoffPortland Limited. Sales to Doff Portland have exceeded the Directors'expectations in the first few months of the relationship. Doff Portland has theexclusive rights to distribute two of the Group's nutrient products to the homeand garden market in Europe. The Group supplies Doff Portland who thenre-package and sell under its own name as a growth accelerator and foliar feed,and as an own label product for Tesco called Lawn Drought Master. Whilst themain focus of the Group is sales to commercial growers of high value crops, theentry into the home and garden market is a welcome development for the Group.Relationships with companies such as Tesco enhance the Group's credibility inthe agrochemicals market and represent a step forward in the Group's aim toposition itself with retailers and consumers, who in turn are seeking ways ofachieving greater food safety and sustainable agriculture by the introduction ofacceptable, non-threatening technology. In April 2007, the Group shipped its first container of nutrient products to theUnited States of America for commercial evaluation on fruit and vegetables,following receipt of an order from an independent manufacturer of fertilisers. Product registration The Group is in the process of finalising its registration dossiers for each ofthe UK Pesticides Safety Directorate ("PSD") and the USA Environment ProtectionAgency ("EPA") for its BugOil(R) product. Following the pre-submission of thedossiers, both the PSD and EPA have asked the Group for additional data, forwhich further tests have been arranged. This is expected to delay completion ofthe registration process until later in 2008. Evaluation trials of BugOil(R) with potential commercial partners continue. TheDirectors hope to enter into a number of licensing and/or distributionagreements for BugOil(R), covering different territories and markets, before theregistration process is complete. The first is a distribution agreement for theEuropean home and garden market that forms part of the Doff Portland contractentered into in December 2006. Product development The Group continues to obtain good results from field trials. For example, astudy conducted by CABI Bioscience, a United Nations treaty organisationdedicated to research in the area of sustainable agriculture, has completed itsthird year of testing nutrients on cocoa in Costa Rica, and has consistentlyshown increased marketable yield of over 50%. A number of potential commercial partners have entered into evaluationagreements to enable them to gain a better understanding of the benefits ofusing the Group's products. These agreements include non-analysis andconfidentiality arrangements covering Plant Impact's ownership of thetechnology. In total over 40 field trials have been conducted around the worldsince 2003, the results from which have been used to assist in the developmentof the Group's products as well as to provide data for potential commercialpartners to use in their own marketing material. Trials that have been initiatedin recent months include: nutrients on protected crops (tomatoes, melons,strawberry and pepper), nutrients on fruit crops (apples and grapes) andnutrients on field crops (potatoes and oils seed rape) in France, Spain and theUK. BugOil(R) trials on protected crops (tomatoes) and ornamentals (roses andchrysanthemums) are ongoing in the EU and the USA. In January 2007, the Groupentered into a research agreement with Lancaster University to assist the Groupin the development of Alethea(R). In field trials Alethea(R) has already beenshown to protect crops against abiotic stress, that is environmental stress suchas extremes of temperature or drought. The technology behind Alethea(R) isincorporated in some of the Group's existing products and is being developed tomarket it as an additive to existing, mass-produced fertilizer products toreduce stress and increase yield. The agreement with Lancaster University is fora project to seek greater clarification of the mechanism of action of Alethea(R)by reference to the physiology and molecular biology of tomatoes, the studycrop. Management team appointments Mike Panteli was appointed Finance Director on 8 May 2007. Mike moved fromIntercytex Group plc ("Intercytex"), where he served as Financial Controller.During his six years at Intercytex, he was a key member of the finance andmanagement teams overseeing the development of Intercytex from a venture capitalbacked biotechnology company through to admission to trading on AIM. Prior toIntercytex, he served as Financial Director of Telescope Technologies Limited, amanufacturer of large telescopes. He replaced Gordon Harman, who indicated atthe time of the admission of the Company to trading on AIM that he wished tostep down from the role of part-time Finance Director by mid-2007. On behalf ofthe Board, I would like to thank him for his assistance in guiding the Companythrough its pre-IPO financing and admission. Gordon remains on the board as anon-executive director. Since the year end, we have also made two important appointments to enhance oursales effort: Martyn Pearce joined Plant Impact in May 2007 as International DevelopmentDirector. Martyn previously worked for Kanesho Soil Treatment, where he held theposition of International Product Manager. He will be responsible for developingchannels to market for our ground breaking anti-stress technologies, as well asthe registration of our botanical insect control product. Martyn has spent allhis working life in the agrochemical industry mostly in technical managementroles for Certis Europe and ISK Biosciences. He is a graduate Biologist with anM.Sc. in Bio-aeronautics. Angel Ruiz joined Plant Impact in June 2007 as Business Development Manager.Angel previously worked for Certis Spain and is an integrated pest management(IPM) and soil fumigation specialist. During his four years at Certis, Angelhelped to establish Certis as a credible IPM company and a major soil fumigationcompany. Angel's responsibilities are to enhance the exposure of Plant Impactproducts in the European and Mediterranean regions. Scientific Advisory panel During the year, the Group formed a small scientific advisory panel, made up ofDr David Dent and Dr Alan Jutsum. The panel held its first meeting withmanagement and other key stakeholders in November 2006, following which theDirectors refined their strategic plan for the business. The panel is expectedto meet with management twice a year. David Dent is an independent consultant,having been Managing Director of CABI Bioscience. He has over 20 yearsexperience in securing international agricultural based research and developmentcontracts and specialises in sustainable agriculture, pest management and thedevelopment and commercialisation of bio pesticides as alternatives tochemicals. Dr Alan Jutsum is the Managing Director of CEMAS, a contract researchorganisation registered to carry out trials and laboratory studies suitable forsubmission for pesticide registration in the USA and UK. He is one of theco-authors of the expert's report that formed part of the Company's admissiondocument. International Financial Reporting Standards The Group intends to implement International Accounting Standards (IFRS) for allfinancial statements in respect of periods commencing after 1 January 2007. Theinterim financial statements for the six months to September 2007 and thecomparatives for the period to September 2006 will therefore be prepared inaccordance with IFRS. The Group is well advanced in its planning for thetransition and is aware of the key impacts of the change. Dividends As stated in the AIM Admission document, the Directors currently intend todevote the Company's cash resources to its operations and therefore do notanticipate paying dividends in the near future. They will reconsider theCompany's dividend policy as and when the Company is in a position to paydividends. The declaration and payment by the Company of any dividends willdepend on the results of the Company's operations, its financial condition, cashrequirements, future prospects, profits available for distribution and otherfactors deemed to be relevant at the time. Outlook The Directors believe that Plant Impact will continue to make progress in theMiddle East, North Africa and European markets through its establisheddistribution channels. Sales in the USA and in the European home and gardenmarket in the latter part of the year have opened up these markets for the Groupsooner than the Directors had expected. Evaluation field trials, on both theGroup's crop nutrient and botanical pesticide products, are being conducted by anumber of multi-national agricultural chemicals companies in America, Japan, theMiddle East and North Africa, Spain and Chile, with a view to them entering intodistribution and/or licensing agreements. The Directors remain confident of thesuccessful development and commercialisation of our products. Martin Robinson Chairman 2 July 2007 Consolidated profit and loss account for the year ended 31 March 2007 Year Restated ended Period ended 31 March 31 March 2007 2006 Note £ £ Turnover - continuing 377,237 345,811 Cost of sales (268,987) (261,517) Gross profit 108,250 84,294 Distribution costs (119,433) (149,518)Research and development costs (721,190) (148,123)General and administrative expenses (763,606) (706,747)Total expenses (1,604,229) (1,004,388) Operating loss - continuing (1,495,979) (920,094) Interest receivable 70,599 6,166Interest payable and similar charges (443,857) (146,460) (373,258) (140,294) Loss on ordinary activities before taxation (1,869,237) (1,060,388) Taxation on loss on ordinary activities 5 98,010 (4,024) Loss on ordinary activities after taxation (1,771,227) (1,064,412) Basic and diluted loss per share 6 (0.12) (1.74) There are no recognised gains and losses other than the loss of £1,771,227attributable to the shareholders for the year ended 31 March 2007 (2006: loss of£1,064,412, as restated). Consolidated balance sheet as at 31 March 2007 Notes Restated 2007 2006 £ £Fixed assetsIntangible assets 554,973 585,383Tangible assets 6,842 3,746 561,815 589,129 Current assetsStocks 3,030 7,831Debtors 223,035 425,509Short-term investments 2,775,000 -Cash at bank and in hand 302,959 446,770 3,304,024 880,110 Creditors: amounts falling due within one year (384,460) (670,717) Net current assets 2,919,564 209,393 Total assets less current liabilities 3,481,379 798,522 Creditors: amounts falling due after more than oneyear - (979,323) Net assets / (liabilities) 3,481,379 (180,801) Capital and reservesCalled up share capital 7,11 231,193 79,878Share premium account 11 6,019,263 844,812Other reserve 11 188,456 80,815Merger reserve 11 182,892 182,892Profit and loss account 11 (3,140,425) (1,369,198) Shareholders' funds 11 3,481,379 (180,801) Consolidated cash flow statement for the year ended 31 March 2007 Year ended Period ended 31 March 31 March Notes 2007 2006 £ £Net cash outflow from operating activities 9 (1,032,168) (1,173,043)Returns on investments and servicing of finance Interest received 63,362 6,166Interest paid (49,778) (40,539) 13,584 (34,373)Capital expenditure and financial investmentPurchase of tangible fixed assets (6,881) (2,495)Acquisitions and disposalsNet cash acquired with subsidiaries 33,961Net cash outflow before management of liquid resources (1,025,465) (1,175,950)Management of liquid resourcesIncrease in short term deposits (2,775,000) -Net outflow before financing (3,800,465) (1,175,950)FinancingIssue of ordinary share capital * 7 3,428,766 730,172Issue of convertible loan notes 2008 100,000 870,985Receipt of bank loan - 15,556Issue of loan notes 143,444 -Repayment of bank loan (15,556) - 3,656,654 1,616,713(Decrease)/increase in cash 10 (143,811) 440,763 Net cash inflow after financingNet cash outflow before management of liquid resources (1,025,465) (1,175,950) 3,656,654 1,616,713Net cash inflow 2,631,189 440,763 * net of issue costs of £586,774 of which £162,540 has been charged to theprofit and loss account and included in net cash outflow after operatingactivities. 1. Basis of preparation The announcement has been prepared under the historical cost convention and inaccordance with applicable accounting standards in the United Kingdom. Theprincipal accounting policies of the Group remained unchanged from the previousperiod with the exception that during the year, the Group implemented theaccounting standard FRS 20 'Share-Based Payments'. This implementation resultedin a restatement of prior year balance sheets and profit and loss accounts. Theimpact of the new standard on prior years is a charge of £80,815 and on thecurrent year is a charge of £107,641 with corresponding entries to equity. The financial information contained in this announcement does not constitutestatutory accounts as defined in section 240 of the Companies Act 1985. Theconsolidated balance sheet at 31 March 2007 and the consolidated profit and lossaccount, consolidated cash flow statement and associated notes for the year thenended have been extracted from the Group's 2007 statutory financial statementsupon which the auditors opinion is unqualified and does not include anystatement under section 237(2) of the Companies Act 1985. Those financialstatements have not been delivered to the Registrar of Companies. The figuresfor the period ended 31 March 2006 have been extracted from the statutoryfinancial statements, as amended by the adoption of FRS 20, which have beenfiled with the Registrar of Companies. 2. Revenue Recognition Revenue is recognised to the extent that the Group obtains the right toconsideration in exchange for its performance. Revenue is measured at the fairvalue of the consideration received, excluding discounts and VAT. Revenue from the sale of goods is recognised when the significant risks andrewards of ownership of the goods have passed to the buyer, usually on dispatchof the goods or on proof of acceptance by the customer. 3. Research and development tax credit Credit is taken in the accounting period for research and development taxcredits, which will be claimed from Her Majesty's Revenue & Customs, in respectof qualifying research and development costs. Credit is taken when there iscertainty of receipt. 4. Share-based payments The cost of equity-settled transactions with employees is measured by referenceto the fair value at the date at which they are granted and is recognised as anexpense over the vesting period, which ends on the date on which the relevantemployees become fully entitled to the award. Fair value is determined using theBlack Scholes pricing model. In valuing equity-settled transactions, no accountis taken of any vesting conditions, other than conditions linked to the price ofthe shares of the company (market conditions). No expense is recognised for awards that do not ultimately vest, except forawards where vesting is conditional upon a market condition, which are treatedas vesting irrespective of whether or not the market condition is satisfied,provided that all other performance conditions are satisfied. At each reporting date, the cumulative expense recognised for equity-basedtransactions reflects the extent to which the vesting period has expired and thenumber of awards that, in the Directors' opinion, will ultimately vest. Themovement in cumulative expense since the previous balance sheet date isrecognised in the profit and loss account, with a corresponding entry in equity. The share-based charges are recognised within the financial statements of thesubsidiary company, P.I. Bioscience Limited, with corresponding increases inequity, as the services provided by the employees and directors were in respectof this subsidiary. The Company is deemed to receive additional benefit from itsinvestment in the subsidiary that is receiving the employees' services. On thisbasis, the Company has capitalised the share-based payment cost as an increaseto its fixed asset investment in P.I. Bioscience Limited. 5. Taxation on loss on ordinary activities Year ended Period ended 31 March 2007 31 March 2006 The tax (credit) / charge is based on the loss for the period and represents: £ £United Kingdom corporation tax at 30% (2006: 30%) (98,010) 4,024 Factors affecting the tax (credit) / charge for the period The tax assessed for the period differs from the standard rate of corporationtax in the United Kingdom of 30%. The differences are explained as follows: Restated Period ended Year ended 31 March 2006 31 March 2007 £ £ Loss on ordinary activities before taxation (1,869,237) (1,060,388)Loss on ordinary activities before taxation multiplied by standardrate of (560,771) (318,116)corporation tax in the United Kingdom of 30% (2006: 30%)Effect of:Expenses not deductible for tax purposes 180,516 55,720Differences between capital allowances for the period and 1,125 777depreciationOther timing differences 64,391 7,853Unrelieved tax losses 323,862 257,790Adjustments to charge in respect of prior periods (4,024) -R&D tax credit (103,109) -Total current tax (98,010) 4,024 Unrelieved tax losses of £2,401,032 (2006: £1,321,492) remain available tooffset against future taxable trading profits. There is a potential deferred taxasset of £720,310 (2006: £396,448) which has not been recognised in thefinancial statements in respect of these trade losses carried forward. 6. Loss per share The loss per share has been calculated in accordance with FRS 22 "Earnings pershare", by dividing the loss for the year by the weighted average number ofordinary shares in issue during the year based on the following information: Restated Year ended 31 March Period ended 2007 31 March 2006 £ £ Loss attributable to the shareholders £ (1,771,227) (1,064,418)Basic weighted average number of shares No 14,869,506 612,820Loss per ordinary share £ (0.12) (1.74) The exercise of share options would have the effect of reducing the loss perordinary share and is not therefore dilutive under the terms of FRS 22. 7. Share capital Authorised 31 March 2007 31 March 2006 Number £ Number £Ordinary shares of 1p each 50,000,000 500,000 10,000,000 100,000 Allotted, called up and fully paid 31 March 2007 31 March 2006 Number £ Number £Ordinary shares of 1p each 23,119,323 231,193 798,775 79,878 On 28 September 2006, each existing and unissued ordinary share of 10p each inthe capital of the Company was sub-divided into 10 ordinary shares of 1p eachsubject to the rights set out in the new articles of association. The authorisedshare capital of the Company was increased from £100,000 to £500,000 by thecreation of 40,000,000 new ordinary shares. On 16 October 2006, the Company was admitted to AIM which resulted in the issueof 10,139,475 new ordinary shares. A further 4,334,204 ordinary shares wereissued on conversion of Convertible Loan Notes 2008 and a further 657,894ordinary shares were issued on capitalization of the RisingStars Growth Fundloan of £250,000. Total gross proceeds from flotation and loan conversion of£5,750,000 were received and the associated issue costs allocated to SharePremium Account amounted to £424,234. The gross proceeds of £5,750,000 comprise of flotation funding of £3,853,000(total cost of £586,774) giving net receipts from flotation of £3,266,226,together with conversion of the secured convertible loan notes 2008 of£1,500,000, conversion of the RisingStars and Lancashire County Developmentsfund loans of £147,000 and capitalisation of the RisingStars Growth Fund loan of£250,000. 8. Share options The Company has a share option scheme for all employees of the Group. Optionsare exercisable at a price equal to the average quoted market price of theCompany's shares on the date of grant. The vesting period is two years. If theoptions remain unexercised after a period of ten years from the date of grantthe options expire. Options are forfeited if the employee leaves the Groupbefore the options vest. Details of the share options outstanding during the year are as follows. 31 March 2007 31 March 2006 Number of Weighted average Number of Weighted average share exercise price share options exercise price options * £ £Outstanding at the beginning of the period 1,055,330 0.25 - -Granted during the period 1,881,546 0.38 1,055,330 0.25Outstanding at the end of the period 2,936,876 0.34 1,055,330 0.25 * Prior to admission to AIM each existing issued and unissued ordinary share of10p each in the capital of the Company was sub-divided into 10 ordinary sharesof 1p each. The options outstanding at 31 March 2007 had a weighted average exercise priceof 34p, and a weighted average remaining contractual life of 2.0 years. Duringthe period to 31 March 2006, options were granted on 10 November 2005, theaggregate of the estimated fair values of the options granted on that date is£166,124. During the period to 31 March 2007, options were granted on 16 October2006, the aggregate of the estimated fair values of the options granted on thosedates is £253,632. The inputs into the Black Scholes option pricing model are as follows: 31 March 2007 31 March 2006Weighted average share price £0.38 £0.30Weighted average exercise price £0.34 £0.25Expected volatility 50% 50%Expected life 2.0 years 2.4 yearsRisk-free rate 4.57 4.35Expected dividends - - Given the lack of share price trading history for Plant Impact plc the expectedvolatility has been estimated by reference to historic volatility of a sample ofcomparative companies. The expected life used in the model has been adjusted,based on management's best estimate, for the effects of non-transferability,exercise restrictions, and behavioural considerations. The group recognised total expenses in the period of £107,641 (2006: £80,815).The expense for 2006 has been treated as a prior year adjustment. 9. Reconciliation of operating loss to net cash outflow Year ended 31 March Period ended 31 2007 March 2006 £ £Operating loss (1,495,979) (920,094)Depreciation 3,785 3,058Amortisation of goodwill 30,410 22,807Amortisation of patents - 15,523Share-based compensation 107,641 80,815Deferred finance costs on convertible loan notes 2008 30,155 -Release of grant income - (3,273)Decrease / (increase) in stock 4,801 (2,831)Decrease / (increase) in debtors 307,720 (263,477)Decrease in creditors (20,701) (105,571)Net cash outflow from operating activities (1,032,168) (1,173,043) 10. Summary of movement in net funds / (debt) Other non-cash movements At 1 April 2006 At 31 March 2007 £ £ Cash flow £ £Cash at bank and in hand 446,770 (143,811) - 302,959Short-term investments - 2,775,000 - 2,775,000Bank loans (15,556) 15,556 - -Convertible loan notes 2008 (979,323) (100,000) 1,079,323 -Loan notes - (143,444) 143,444 -Other loans (250,000) - 250,000 - (798,109) 2,403,301 1,472,767 3,077,959 11. Reconciliation of shareholders' funds and movement on reserves Called up Share Other Merger Profit and Total share premium reserves reserve loss account shareholders' capital account funds £ £ £ £ £ £At 1 April 2006 - as 79,878 844,812 - 182,892 (1,288,383) (180,801)previously statedPrior year adjustment - FRS20 - - 80,815 - (80,815) -At 1 April 2006 - as restated 79,878 844,812 80,815 182,892 (1,369,198) (180,801)Loss for the period - - - - (1,771,227) (1,771,227)Share-based compensation - - 107,641 - - 107,641Issue of ordinary shares * 151,315 5,174,451 - - - 5,325,766 At 31 March 2007 231,193 6,019,263 188,456 182,892 (3,140,425) 3,481,379 *net of issue costs of £424,234. Other Reserves Other reserves comprise the fair value provision for the costs of optionsgranted. - Ends - This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Plant Impact